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INTRODUCTION
Carcinoma of the Rectum represents one of the prime challenges to the medical 
profession because they arise in polyps and produce symptoms relatively early and at a 
stage generally curable by resection.
Carcinoma of the Rectum is a major cause of morbidity and mortality.  Incidence 
of carcinoma of the rectum has been on the rise over the past 10 years. This may be 
attributed to changing trends in lifestyle, such as adoption of western diet.
Almost all rectal cancers are primary adenocarcinomas (98%). Carcinoid (0.1%), 
Lymphoma (1.3%), and sarcoma (0.3%) are rare varieties of  carcinoma of the rectum.
The 5-year survival rate is approximately 50%. Early diagnosis and appropriate 
therapeutic intervention will improve the survival rate.
AIMS OF THE STUDY
The aims of the study are 
(1) to know the incidence of the carcinoma of the rectum with regard to age and sex
(2) to understand the clinical pattern and presentation
(3) to understand the pathology
(4) to know the site of the malignancy from the anal verge
(5) to know the role of various investigations
(6) to evaluate appropriate investigations
(7)  to know the morbidity and mortality
ANATOMY
The rectum lies anterior to the sacrum and coccyx and is approximately 15 cm 
long.  The rectosigmoid junction is located at  the end of the sigmoid mesocolon.  Its 
upper  third  is  covered  almost  completely  by  peritoneum.  Below  this  level,  the 
peritoneum is reflected anteriorly onto the posterior surface of the uterus and vagina in 
females and onto the posterior surface of the bladder in males. The peritoneal recesses, 
the  pouch  of  Douglas  (rectouterine),  and  the  rectovesical  pouch  lie  between  these 
organs. 
The lower half  of the rectum is entirely extraperitoneal.  The rectum ends just 
below the level of the coccyx. It turns posteriorly through the puborectal sling of the 
levator ani muscles to become the anal canal. The rectum is supplied by the superior 
rectal branch of the inferior mesenteric artery and from branches of the internal iliac 
arteries. The rectal lymphatics drain superiorly into the superior rectal, then the inferior 
mesenteric nodes, and laterally into the internal iliac nodes. 
The rectal wall comprises 5 layers, including the (1) mucosa (lined with columnar 
epithelium),  (2)  muscularis  mucosa,  (3)  submucosa,  (4)  muscularis  propria (an inner 
circular  layer  and an  outer  longitudinal  layer,  comprising  3  narrow bands),  and  (5) 
serosa. 
EPIDEMIOLOGY
Frequency: 
Colorectal  cancers  are  the second most  common cause of  cancer  death in the 
developed countries and the most common GI cancer. The incidence of the rectal cancer 
is the highest in the westernized countries of North America, Northern Europe, Australia 
and New Zealand. Intermediate rates are found in Southern Europe and low rates in 
Africa, Asia and South America .Rectal cancers shows less international variations than 
colon cancer. High colon – to-rectal cancer ratios prevail in the westernized countries 
.Ratios equalizing less than one are typical in Asia and Africa.
Race: 
Western nations tend to have a higher incidence than Asian and African countries; 
however, within the United States, little difference in incidence exists among whites, 
African Americans, and Asian Americans. Among religious denominations, colorectal 
cancer occurs more frequently in the Jewish population. 
Sex: 
The  incidence  of  colorectal  malignancy  is  slightly  higher  in  males  than  in 
Females. 
Age:
Incidence  peaks  in  the seventh  decade;  however,  cases  have  been reported  in 
young children
ETIOPATHOGENESIS
The etiology of colorectal cancer is unknown but appears to be multi-factorial in 
origin and includes environmental factors and a genetic component. Diet may have an 
etiologic role, especially diet with high fat content. Approximately 75% of colorectal 
cancers are sporadic and develop in people with no specific risk factors. The remaining 
25% of cases occur in people with significant risk factors. Most (15-20%) colorectal 
cancers develop in people with either a positive family history or a personal history of 
colorectal cancer or polyps. The remaining cases occur in people with certain genetic 
predispositions, such as hereditary nonpolyposis colorectal cancer (HNPCC, 4-7%) or 
familial  adenomatous  polyposis  (FAP,  1%)  or  in  people  with  inflammatory  bowel 
disease (IBD, 1%).
Environmental factors
Diet 
A high-fat, low-fiber diet is implicated in the development of colorectal cancer. 
Specifically,  people  who  ingest  a  diet  high  in  unsaturated  animal  fats  and  highly 
saturated  vegetable  oils  (E.g.  corn,  safflower)  have  a  higher  incidence  of  colorectal 
cancer.  Saturated fats  from dairy products  do not  have  the same effect,  nor  do oils 
containing oleic  acid (e.g.  olive,  coconut,  fish oils).  Omega-3 monounsaturated fatty 
acids and omega-6 monounsaturated fatty acids also appeared to be less carcinogenic 
than unsaturated or polyunsaturated fats. 
The  mechanism by  which  these  substances  are  related  to  the  development  of 
colorectal cancer is unknown. The ingestion of a high-fiber diet appears to be protective 
against colorectal cancer. Fiber causes the formation of a soft, bulky stool that dilutes 
out carcinogens; it also decreases colonic transit time, allowing less time for harmful 
substances  to  contact  the  mucosa.  The  decreased  incidence  of  colorectal  cancer  in 
Africans is attributed to their high-fiber, low–animal-fat diet. This favorable statistic is 
reversed when Africans adopt a western diet.
Increased  dietary  intake  of  calcium  appears  to  have  a  protective  effect  on 
colorectal mucosa by binding with bile acids and fatty acids. The resulting calcium salts 
may  have  anti-proliferative  effects,  decreasing  crypt  cell  production  in  the  mucosa. 
Other dietary components, such as selenium, carotenoids, and vitamins A, C, and E, may 
have protective effects by scavenging free-oxygen radicals in the colon. 
Alcohol
Daily alcohol drinkers experience a 2-fold increased risk of developing colorectal 
carcinoma. Specifically, beer consumption in excess of 15 liters per month increases the 
risk of rectal cancer in men.
Hereditary factors
Family history 
The relative risk of developing colorectal cancer is increased in the first-degree 
relatives of affected patients. The relative risk of developing this malignancy if 1 first-
degree family member  is  affected with colorectal  cancer  is  1.72;  with 2 first-degree 
family members affected, the relative risk increases to 2.75. If the first-degree family 
member  is  younger  than  45  years  at  the  time  of  diagnosis,  the  risk  increases  to 
5.37.Personal history of colorectal cancer or polyps: Of patients with colorectal cancer, 
30% have synchronous lesions, usually adenomatous polyps. Approximately 40-50% of 
patients  have  polyps  on  follow-up colonoscopy.  Of  patients  who have  adenomatous 
polyps on colonoscopy, 29% have additional polyps on repeat colonoscopy 1 year later. 
Malignancy develops in 2-5% of patients. The risk of cancer in people who have had 
polyps removed is 2.7-7.7 times that of the general population.
Genetic disorders
Familial adenomatous polyposis 
FAP is an autosomal dominant inherited syndrome that results in the development 
of more than 100 adenomatous polyps and a variety of extraintestinal manifestations. 
The defect is in the  APC gene, which is located on chromosome 5 at locus q21. The 
disease process causes the formation of hundreds of intestinal polyps, osteomas of the 
bone, desmoid tumors, and, occasionally, brain tumors. Individually, the polyps do not 
have a risk of malignant transformation greater than polyps in the general population. 
The  increased  number  of  polyps,  however,  predisposes  patients  to  a  greater  risk  of 
cancer. If left untreated, colorectal cancer develops in nearly 100% of these patients by 
age 40 years. While the hereditary link is documented, approximately 20% of FAP cases 
are caused by spontaneous mutation.
Hereditary nonpolyposis colorectal cancer
HNPCC is  an autosomal  dominant  inherited syndrome that  occurs  because  of 
defective mismatch repair genes located on chromosomes 2, 3, and 7. Patients have the 
same number of polyps as the general population, but their polyps are more likely to 
become malignant. These patients also have a higher incidence of endometrial, gastric, 
thyroid, and brain cancers.
Inflammatory bowel disease
Ulcerative colitis 
The  incidence  of  malignancy  increases  with  duration.  After  10  years,  the 
incidence of colorectal cancer in ulcerative colitis (UC) is approximately 1% per year. 
Evaluate  patients  for  dysplastic  changes  with  annual  colonoscopy.  Dysplasia  is  a 
precursor of cancer and, when present, the risk of cancer is 30%.
Crohn disease 
The incidence of colorectal cancer in patients with Crohn disease is 4-20 times 
greater than that of the general population. Cancer occurs in patients with disease of at 
least 10 years' duration. The average age at diagnosis (i.e. 46-55 y) is younger than that 
of  the  general  population.  Cancers  often  develop  in  areas  of  strictures  and  in  de-
functionalized segments of intestine. 
Pathophysiology
Carcinomas  are  found  in  as  many  as  4%  of  neoplastic  polyps.  Cells  must 
accumulate 4-5 molecular defects, including activation of oncogenes and inactivation of 
tumor suppressor genes, to undergo malignant transformation. In normal mucosa, the 
surface epithelium regenerates approximately every 6 days. Crypt cells migrate from the 
base of the crypt to the surface, where they undergo differentiation, maturation, and, 
ultimately, lose the ability to replicate. In adenomas, several genetic mutations alter this 
process,  starting  with  inactivation  of  the  adenomatous  polyposis  coli  (APC)  gene, 
allowing unchecked cellular replication at the crypt surface. With the increase in cell 
division, further mutations occur, resulting in activation of the K-ras oncogene in the 
early  stages  and  p53 mutations  in  later  stages.  These  cumulative  losses  in  tumor 
suppressor gene function prevent apoptosis and give the cell eternal life. 
Macroscopic appearance
(1) Ulcerative     -  presents as a malignant lesion with raised and irregular    
                     everted edges and sloughed floor
(2) Proliferative - Has an irregular nodular surface and is friable and bleeds 
                              early
(3)Annular         -  It tends to involve the wall of the rectum but does not 
                              project into the rectum. Usually causes obstruction
(4) Infiltrating    -  Causes diffuse thickening of the wall. 
Histological grading
 In  the  great  majority  of  cases,  carcinoma  of  the  rectum is  a  columnar-celled 
adenocarcinoma.  The  more  nearly  the  tumor  cells  approach  normal  shape  and 
arrangement, the less malignant is the tumor. Conversely, the greater the percentage of 
cells of an embryonic or undifferentiated type, the more malignant is the tumor.
Low grade               Well-differentiated            Prognosis good
Average grade         Averagely-differentiated   Prognosis fair
High grade               Anaplastic                         Prognosis poor
Staging: 
Dukes classification
In  1932,  Cuthbert  E.  Dukes,  a  pathologist  at  St.  Mark  Hospital  in  England, 
introduced a staging system for rectal cancer.
His system divided tumor classification into 3 stages, as follows: 
Dukes A Growth limited to the rectal wall 
Dukes B Growth extending through the rectal wall in to extra rectal tissue.
Dukes C Metastasis to regional lymphnodes 
C1 Involvement of local pararectal lymphnodes  
C2 Nodes accompanying the supplying blood vessels are   implicated 
up to the point of division 
A stage D is often included which was not described by Dukes. This stage signifies the 
presence of wide spread metastasis 
ASTLER – COLLER CLASSIFICATION 
A Limited to the mucosa
B1 Extending in to the musularis propria but not penetrating through it; uninvolved 
nodes
B2 Penetrating through musularis propria ; uninvolved nodes
C1 Extending in to the musularis  propria  but  not  penetrating through it;  involved 
nodes
C2 Penetrating through musularis propria ; involved nodes
D Distant metastasis 
Tumor, node, metastasis (TNM) system: 
This system was introduced in 1954 by the American Joint Committee on Cancer 
(AJCC) and the International  Union Against  Cancer  (IUAC).  The TNM system is a 
universal staging system for all solid cancers that is based on clinical and pathologic 
information. Each category is independent. 
Neither  the  Dukes  nor  the  TNM  system  includes  prognostic  information  such  as 
histologic grade, vascular or perineural invasion, or tumor DNA ploidy. 
TNM classification for cancer of the colon and rectum (AJCC)
Primary tumor (T) 
TX - Primary tumor cannot be assessed or depth of penetration not specified 
T0 - No evidence of primary tumor 
Tis - Carcinoma in situ (mucosal); intraepithelial or invasion of the lamina propria 
T1 - Tumor invades submucosa 
T2 - Tumor invades muscularis propria 
T3  -  Tumor  invades  through  the  muscularis  propria  into  the  subserosa  or  into 
nonperitonealized pericolic or perirectal tissue 
T4  -  Tumor  perforates  the  visceral  peritoneum or  directly  invades  other  organs  or 
structures
Regional lymph nodes (N) 
NX - Regional lymph nodes cannot be assessed 
N0 - No regional lymph node metastasis 
N1 - Metastasis in 1-3 pericolic or perirectal lymph nodes 
N2 - Metastasis in 4 or more pericolic or perirectal lymph nodes 
N3 - Metastasis in any lymph node along the course of a named vascular trunk
Distant metastasis (M) 
MX - Presence of metastasis cannot be assessed 
M0 - No distant metastasis 
M1 - Distant metastasis
TNM Stage Grouping for Cancer of the Colon and Rectum 
Stage T N M Dukes Stage
I Tis N0 M0
T1 N0 M0 
T2 N0 M0
A
II T3 N0 M0
T4 N0 M0
B
III Any T N1 M0
Any T N2, N3 M0
IV Any T Any N M1
C
CLINICAL FEATURES
All patients should undergo a complete history, including a family history and 
assessment of risk factors for the development of rectal cancer.  Many rectal cancers 
produce  no  symptoms  and  are  discovered  during  digital  or  proctoscopic  screening 
examinations.
Bleeding
This is the most common symptom of rectal cancer and occurs in 60% of patients. 
Bleeding often is attributed to other causes (e.g. hemorrhoids), especially if the patient 
has a history. Profuse bleeding and anemia are rare. Bleeding may be accompanied by 
the passage of mucus and warrants further investigation.
Change in bowel habits
Present  in  43% of  patients,  this  symptom has  several  different  presentations. 
Often, it  occurs in the form of diarrhea, particularly if the tumor has a large villous 
component. These patients may have hypokalemia on laboratory studies. The capacity of 
the rectal reservoir may mask the presence of a small lesion. Some patients experience a 
change in caliber of the stool. Large tumors can cause obstructive symptoms. Tumors 
located low in the rectum can cause a feeling of incomplete evacuation and tenesmus. 
Occult bleeding: 
This is detected on screening fecal occult blood test (FOBT) in 26% of cases.
Abdominal pain
Partial large-bowel obstruction may cause colicky abdominal pain and bloating 
and is present  in 20% of cases.  Back pain usually is  a late sign caused by a tumor 
invading or  compressing nerve trunks.  Urinary symptoms may occur if  the tumor is 
invading or compressing the bladder or prostate. 
Malaise
 This nonspecific entity is the presenting symptom in 9% of cases. 
Bowel obstruction: 
Complete obstruction of the large bowel is rare and is the presenting symptom in 
9% of cases. 
Pelvic pain:
This late symptom usually indicates nerve trunk involvement and is present in 5% 
of cases.
Other presentations include emergencies such as peritonitis from perforation (3%) 
or jaundice, which may occur with liver metastases (<1%).
Physical Examination 
Physical  examination  is  performed  with  specific  attention  to  possible 
metastatic lesions, including enlarged lymph nodes or hepatomegaly. The remainder of 
the colon also is examined.
Digital rectal examination 
The easy  accessibility  of  the rectum provides an opportunity  to readily  detect 
abnormal lesions via digital  rectal examination (DRE). The average finger can reach 
approximately 8 cm above the dentate line. Tumors can be assessed for size, ulceration, 
and  presence  of  any  pararectal  lymph  nodes.  Fixation  of  the  tumor  to  surrounding 
structures (e.g. sphincters, prostate, vagina) also can be assessed. DRE also permits a 
cursory  evaluation  of  the  patient's  sphincter  function.  This  information  is  necessary 
when determining whether a patient is a candidate for a sphincter-sparing procedure.
INVESTIGATIONS
Lab Studies: 
Routine  laboratory  studies  should  include  a  complete  blood  count;  serum 
chemistries, including liver and kidney function tests; and a carcinoembryonic antigen 
(CEA) test.
Metastatic workup
Liver function tests usually are part of the preoperative workup; these test results 
often are normal even with metastases to the liver.
Carcinoembryonic antigen test: 
Perform a CEA test in all patients with rectal cancer. A baseline level is obtained 
before  surgery  and a  follow-up  level  is  obtained after  surgery.  This  may  alert  to  a 
possible recurrence if a previously normalized CEA begins to rise in the postoperative 
period. A CEA higher than 100ng/mL usually indicates metastatic disease and warrants 
a thorough investigation.
Imaging Studies
Proctoscopy
The proctoscope enables visual examinations to be made of the lower part of the 
rectum and the anal canal. The mucous membrane of the rectum is examined and any 
abnormalities such as inflammation, ulceration, or tumor are noted.
Sigmoidoscopy 
The  60-cm  flexible  sigmidoscope  has  a  increased  range  over  the  rigid 
sigmoidoscope  which  at  best  reaches  only  to  the  rectosigmoid  (30-cm).It  can  be 
performed  without  an  anaesthestic,  allows  direct  visualization  of  the  rectum  and 
provides an  estimation of  the size  of  the lesion  and the degree of  obstruction.  This 
procedure is used to obtain biopsies of the lesion, assess ulceration, and determine the 
degree of fixation. In addition, it gives an accurate measurement of the distance of the 
lesion  from  the  dentate  line;  the  latter  is  critical  in  deciding  which  operation  is 
appropriate.
Endorectal ultrasound
Endorectal ultrasound (ERUS) is an invaluable tool in assessing depth of invasion 
of rectal cancers; it is 72-94% accurate.
The accuracy of detection of lymph node involvement ranges from 73-86%. Most of 
these nodes are larger than 1 cm. Smaller nodes can be detected, but the accuracy of 
determining tumor involvement is less than the accuracy for larger nodes.
Overestimation of staging and nodal involvement occurs more often than under 
staging. This probably is due to the inflammatory process caused by the tumor.
ERUS visualizes the rectal wall as alternating hyperechoic and hypoechoic layers 
of tissue. The first layer is the hyperechoic water-filled balloon or mucosal interface, 
which is bounded by the hypoechoic mucosa and muscularis mucosa, the hyperechoic 
submucosa, the hypoechoic muscularis propria, and, finally, the hyperechoic muscularis 
mucosa or  perirectal  fat  interface.  Depth of penetration is  determined by identifying 
which of these layers is disrupted by the tumor.
ERUS also is useful in determining invasion of surrounding structures and the 
presence of local recurrence when used after surgery.
Endorectal  surface-coil  MRI:  An  alternative  to  ERUS,  this  technique  is  touted  as 
equally or more accurate than ERUS in lymph node staging.
Metastatic workup
Chest radiograph: 
Obtain  a  chest  radiograph to  rule  out  pulmonary  metastases  and to  determine 
whether the patient has any gross underlying pulmonary disease, including emphysema.
CT scan: 
This study generally is used to determine the presence or absence of metastases. 
CT scans can identify lesions in the liver, adrenals, ovaries, lymph nodes, and 
other  organs.  In  10%  of  patients,  the  CT  scan  misses  small  liver  lesions.  When 
combined with an angiogram, a CT scan is 95% accurate in identifying liver metastases. 
Some information can be gleaned from a CT scan regarding depth of penetration 
of the primary rectal tumor. When performed with rectal contrast given as an enema, CT 
scans can determine the depth of penetration accurately in 84% of cases. 
CT scan detects lymph nodes larger than 1 cm in 75% of cases. 
CT  scans  are  helpful  in  determining  whether  patients  require  preoperative 
chemoradiation therapy.
MRI actually  is  the  most  sensitive  test  for  determining  the  presence  of  liver 
metastases and often is used if liver resection is considered.
Positron emission tomography: 
The  major  advantage  of  a  positron  emission  tomography  (PET)  scan  is  to 
differentiate between recurrent tumor and scar tissue by measuring tissue metabolism of 
an injected glucose-based substance. Scar tissue is inactive, whereas tumor generally is 
hypermetabolic.  This  test  generally  is  not  used  in  a  routine  preoperative  metastatic 
workup.
CEA scan: 
If routine imaging studies cannot detect the area of metastatic disease, a CEA scan 
can be performed. Radioimmunoscintigraphy uses radiolabeled antibodies to CEA and 
total-body scanning to determine the location of CEA-producing metastases. This test is 
not used routinely in the preoperative evaluation, and its value is controversial.
TREATMENT
Preoperative radiation therapy
The  potential  advantages  of  this  treatment  include  tumor  down-staging;  an 
increase in resectability, possibly with a sphincter-sparing procedure; and a decrease in 
tumor viability, which may decrease the risk of local recurrence. 
The  disadvantages include  delaying surgery,  possible  loss  of  accurate  surgical 
staging, and increased postoperative morbidity and mortality rates. 
Preoperative  radiation  therapy  (RT)  decreases  the  risk  of  tumor  recurrence  in 
patients with stage II or III disease; however, this does not translate into a decrease in 
distant metastases or an increase in survival rate. Some recent reports cite an increase in 
survival; however, this is still the minority opinion. In patients with stage I disease, the 
morbidity and mortality rates are higher, and preoperative RT has no proven benefit.
Postoperative radiation therapy 
The  advantages  of  postoperative  RT include  immediate  surgery  and  complete 
pathologic information before beginning RT. 
The disadvantages include possible delay in RT if  postoperative complications 
ensue, no effect on tumor cell spread at the time of surgery, and decreased effect of RT 
in surgically induced tissue hypoxia. 
Postoperative RT decreases the rate of local recurrence when compared to surgery 
alone but has not been shown to increase survival.
Chemotherapy/combined modality therapy 
This has been studied extensively. Initial studies using fluorouracil and methyl-
cyclohexylchloroethlynitrosurea (methyl-CCNU) did not demonstrate any decrease in 
local control or distant spread or any increase in survival. 
Other  studies  using  fluorouracil  and  vincristine  showed  some  marginal 
improvement in survival when compared to surgery alone.
Combined modality therapy 
The  combination  of  preoperative  RT and  chemotherapy  with  fluorouracil  and 
methyl-CCNU improves local control,  distant spread, and survival.  The basis of this 
improvement is believed to be the activity of fluorouracil as a radiosensitizer. 
Chemoradiation therapy involves using preoperative RT and fluorouracil with a 
variety  of  other  drugs  such  as  leucovorin  and  irinotecan.  In  some  cases,  surgical 
specimens inspected after this combination therapy have shown a complete response 
with no evidence of residual tumor. While these results are encouraging, further studies 
are  still  necessary  to  determine  long-term  results.  The  dosages  and  administration 
schedules of these chemotherapeutic regimens are left to the discretion of the consulting 
oncologist or may be dictated by experimental protocols. This is beyond the scope of 
this review and is not discussed further.
Surgical Care: 
Transanal excision 
The transanal excision method of local excision of rectal cancer is reserved for only the 
most superficial lesions. Patients with stage 0 or stage I cancer with a T1 lesion are 
candidates for this procedure. 
Tis and T1 lesions are confined to the submucosa of the rectal wall. Lesions in the lower 
one third of the rectum are the most easily accessible and are suited best for transanal 
excision. Preferably, they also should be polypoid, involve less than one third of the 
circumference of the rectal wall, be mildly to moderately well differentiated, and not 
involve the sphincters. The likelihood of lymph node involvement in this type of lesion 
ranges from 0-12%. 
Perform preoperative ERUS. If nodes are identified as suggestive of cancer, do 
not perform transanal excision. 
The lesion is excised with full thickness of the rectal wall, leaving a 1-cm margin 
of normal tissue. The defect usually is closed, although some surgeons leave it open. 
Positive resection margins or involved lymph nodes mandate definitive resection. 
Usually,  an  abdominal  perineal  proctosigmoidectomy  is  performed,  although  some 
facilities attempt sphincter-sparing resections. 
The 5-year survival rate after transanal excision ranges from 65-100% (including 
some T2 lesions). The local recurrence rate ranges from 0-40%. 
Lesions that display unfavorable histologic features but are excised completely 
may be treated with adjuvant radiation therapy. 
Transanal endoscopic microsurgery 
Transanal endoscopic microsurgery is another form of local excision that uses a 
special operating proctoscope that distends the rectum with insufflated carbon dioxide 
and allows the passage of dissecting instruments. 
This method can be used on lesions located higher in the rectum and even the distal 
sigmoid colon. 
Transanal endoscopic microsurgery has not come into wide use yet because of a 
significant learning curve and a lack of availability.
Sphincter-sparing  procedures:  Procedures  are  described  using  the  traditional  open 
technique.  All  of  these  procedures,  except  the  perineal  portions,  can  and have  been 
performed using laparoscopic techniques with excellent results. 
Low anterior resection
Low anterior resection (LAR) generally is performed for lesions in the middle and 
upper third of the rectum and, occasionally, for lesions in the lower third. 
Because this is a major operation, patients who undergo LAR should be in good 
health.  They  should  not  have  any  preexisting  sphincter  problems  or  evidence  of 
extensive local disease in the pelvis. 
Patients  will  not  have  a  permanent  colostomy  but  should  be  informed  that  a 
temporary  colostomy or  ileostomy may  be  necessary.  They  also  must  be  willing  to 
accept the possibility of slightly less-than-perfect continence after surgery, although this 
is not usually a major problem. 
Other  possible  disturbances  in  function  include  transient  urinary  dysfunction 
secondary to weakening of the detrusor muscle. This occurs in 3-15% of patients. Sexual 
dysfunction is more prominent and includes retrograde ejaculation and impotence. In the 
past,  this has occurred in 5-70% of men, but  recent  reports indicate that  the current 
incidence is lower. 
The operation entails full mobilization of the rectum, sigmoid colon, and, usually, 
the  splenic  flexure.  Mobilization  of  the  rectum  requires  a  technique  called  total 
mesorectal excision (TME). 
TME  involves  sharp  dissection  in  the  avascular  plane  that  is  created  by  the 
envelope that separates the mesorectum from the surrounding structures. This includes 
the anterior peritoneal reflection and Denonvilliers fascia anteriorly and preserves the 
inferior hypogastric plexus posteriorly and laterally. 
TME is performed under direct visualization. 
TME yields a lower local recurrence rate (4%) than transanal excision (20%), but 
it is associated with a higher rate of anastomotic leak (11%). For this reason, TME may 
not be necessary for lesions in the upper third of the rectum. 
The distal resection margin varies depending on the site of the lesion. A 2-cm 
margin  distal  to  the  lesion  must  be  achieved.  The  procedure  is  performed  with  the 
patient in the modified lithotomy position with the buttocks slightly over the edge of the 
operating table to allow easy access to the rectum. 
A circular  stapling device is  used to create the anastomosis.  A double-stapled 
technique is performed. This entails transection of the rectum distal to the tumor from 
within the abdomen using a linear stapling device. The proximal resection margin is 
divided with a purse-string device. After sizing the lumen, the detached anvil of the 
circular stapler is inserted into the proximal margin and secured with the purse-string 
suture. The circular stapler is inserted carefully into the rectum, and the central shaft is 
projected through or  near  the linear  staple  line.  Then,  the anvil  is  engaged with the 
central shaft, and, after completely closing the circular stapler, the device is fired. Two 
rings of staples create the anastomosis, and a circular rim or donut of tissue from the 
proximal and distal margins is removed with the stapling device. 
The anastomotic leak rate with this technique ranges from 3-11% for middle-third 
and upper-third anastomoses and to 20% for lower-third anastomoses. For this reason, 
some surgeons choose to protect the lower-third anastomosis by creating a temporary 
diverting stoma. This is especially important when patients have received preoperative 
RT. The rate of stenosis is approximately 5-20%. A hand-sewn anastomosis may be 
performed; if preferred, the anastomosis is performed as a single-layer technique. The 
leak and stenosis rates are the same.
Coloanal anastomosis 
Very distal rectal cancers that are located just above the sphincters occasionally 
can be resected without the need for a permanent colostomy. The procedure is as already 
described;  however,  the  pelvic  dissection  is  carried  down to  below the  level  of  the 
levator  ani  muscles  from within  the  abdomen.  A straight-tube  coloanal  anastomosis 
(CAA)  can  be  performed  using  the  doubled-stapled  technique,  or  a  hand-sewn 
anastomosis can be performed transanally. 
The functional results of this procedure have been poor in some patients,  who 
experience  increased  frequency  and  urgency  of  bowel  movements,  as  well  as  some 
incontinence to flatus and stool. 
An alternative to the straight-tube CAA is creation of a  colonic J pouch.  The 
pouch is created by folding a loop of colon on itself in the shape of a J. A linear stapling 
or cutting device is inserted into the apex of the J, and the stapler creates an outer staple 
line while dividing the inner septum. The J-pouch anal anastomosis can be stapled or 
hand sewn. 
An alternative to doing the entire dissection from within the abdomen is to begin 
the operation with the patient in the prone jackknife position. The perineal portion of 
this procedure involves an intersphincteric dissection via the anus up to the level of the 
levator ani muscles. After the perineal portion is complete, the patient is turned to the 
modified lithotomy position and the abdominal portion is performed. Either a straight-
tube or colonic J-pouch anal anastomosis can be created; however, both must be hand 
sewn. 
The advantages of the J pouch include decreased frequency and urgency of bowel 
movements because of the increased capacity of the pouch. 
A  temporary  diverting  stoma  is  performed  routinely  with  any  coloanal 
anastomosis. 
Abdominal perineal resection
Abdominal  perineal  resection  (APR) is  performed in  patients  with lower-third 
rectal cancers who cannot undergo a sphincter-sparing procedure. This includes patients 
with  complex  involvement  of  the  sphincters,  preexisting  significant  sphincter 
dysfunction, or pelvic fixation, and sometimes is a matter of patient preference. 
A 2-team approach often is used, with the patient in modified lithotomy position. 
One team mobilizes the colon and rectum, transects the colon proximally, and creates an 
end-sigmoid colostomy. 
The  perineal  team begins  by  closing  the  anus  with  a  purse-string  suture  and 
making  a  generous  elliptical  incision.  The  incision  is  carried  through  the  fat  using 
electrocautery. The inferior rectal vessels are ligated and the anococcygeal ligament is 
divided. The dissection plane continues posteriorly, anterior to the coccyx to the level of 
the levator ani muscles. Then, the surgeon breaks through the muscles and retrieves the 
specimen that has been placed in the pelvis. The specimen is brought out through the 
posterior opening, and the anterior dissection is continued carefully. Care must be taken 
to avoid the prostatic capsule in the male and the vagina in the female (unless posterior 
vaginectomy was planned). The specimen is removed through the perineum, and the 
wound is irrigated copiously. A closed-suction drain is left in place, and the perineal 
wound is closed in layers by using absorbable sutures. 
During this time, the abdominal team closes the pelvic peritoneum (this is not 
mandatory), closes the abdomen, and matures the colostomy.
Prognosis: 
Overall 5-year survival rates for rectal cancer are as follows:
Stage I - 72% 
Stage II - 54% 
Stage III - 39% 
Stage IV - 7%
Fifty percent of patients develop recurrence, which may be local, distant, or both.
Local recurrence is more common in rectal cancer than in colon cancer.
Disease recurs in 5-30% of patients, usually in the first 2 years after surgery.
Factors that influence the development of recurrence include surgeon variability, 
grade and stage of the primary tumor,  location of the primary tumor,  and ability to 
obtain negative margins.
Surgical therapy may be attempted for recurrence and includes pelvic exenteration 
or  APR in  patients  who  had  a  sphincter-sparing  procedure.RT generally  is  used  as 
palliative treatment in patients who have locally unresectable disease.
MATERIALS AND METHODS
Patients attending surgical units of Government Stanley Hospital between January 2004 
to February 2006 were included for study.
Patients with history of blood or mucus in the stools and presence of identified 
growth in the rectum detected by DRE or Proctosigmoidoscopy were included for the 
study.
Patients had a detailed history and clinical evaluation. A DRE and proctoscopy 
was done, if a lesion was identified, sigmoidoscopy was performed.
All  the  patients  included  for  study  had  baseline  investigations  done  which 
included Hb%, TC,  DC,  and Renal  function tests.  Liver  function  tests  was  done  to 
evaluate the liver function. USG abdomen and pelvis was done. CT abdomen and pelvis 
was done mandatory in all  patients except  for cases with acute presentation. Double 
contrast enema was done whenever necessary. The patients were also counseled with 
regards  to  colostomy.  Pre-operative  bowel  preparation  was  done  with  polyethylene 
glycol  given  orally  the  day  before  the  surgery  and  on  the  morning  of  surgery. 
Intravenous antibiotics was also given one hour prior to surgery.
All  the  patients  were  subjected  to  surgery  if  the  general  condition  was  good 
enough to permit the same. Preference for a particular surgery depended on the site, 
stage  and  operability  of  the  tumor.  Surgeries  were  either  curative  or  palliative. 
Postoperatively patients were followed up with either chemotherapy in the form of 5-FU 
or Radiotherapy. All the data were recorded  in the proforma for study purpose. 
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Symptoms No. of cases Percentage
Bleeding PR 24 64.90%
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Altered bowel habits 18 48.60%
Tenesmus 12 32.40%
Pain abdomen 8 21.60%
Obstruction 3 8.10%
SIGMOIDOSCOPIC FINDINGS
Macroscopic Appearance No. of cases Percentage
Ulceroproliferative 18 48.60%
Annular 12 32.40%
Tubular 7 19.00%
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< 8 cm 26 70.30%
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Histopathology No. of cases Percentage
WDA 17 45.90%
MDA 12 32.40%
PDA 5 13.50%
OTHERS 3 8.20%
WDA - Well Differentiated Adenocarcinoma.
MDA - Moderately Differentiated Adenocarcinoma.
PDA - Poorly Differentiated Adenocarcinoma.
OTHERS - Malignant melanoma, Burkitt’s lymphoma,
Neuroendocrine tumor. 
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Surgery No. of cases Percentage
APR 24 64.90%
AR 5 13.50%
LAPR 1 2.70%
LAR 2 5.40%
Colostomy 5 13.50%
CAUSES OF INOPERABILITY
Causes No. of cases Percentage
Sacral invasion 1 20.00%
Prostatic invasion 1 20.00%
Frozen pelvis 2 40.00%
Liver metastasis 1 20.00%
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Duke's Staging No. of cases Percentage
A 12 37.50%
B 13 40.60%
C 7 21.90%
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Complications No. of cases
Perineal wound infection 2
Perineal wound gaping 1
Abdominal wound infection 5
Abdominal wound gaping 2
Retention of Urine 10
Sexual dysfunction 3
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DISCUSSION
37 patients were managed during the study period from January 2004 to February 
2006. There were 23 males (62%) and 14 females (38%).  Gilliland et al reported the 
incidence of males in 54% of patients and females in 46% of patients. Studies conducted 
at adyar cancer institute showed the sex ratio of 1.2:1. Other studies showed variation 
from 1.1:1 to 1.8:1. our study shows the sex ratio of 1.6:1.
The range of age is from 18 to 72 years. The peak incidence is in the seventh 
decade. However, more cases are found above the age of fourty years. Issac hussain et al 
in his study quoted increased incidence of cases between 61 to 70 years.
Elizabeth cirincione et al in her study reported bleeding per rectum in 56% of the 
cases as the main complaint with alteration of bowel habits in 28% of the cases. This 
study also shows that bleeding per rectum is the most common clinical presentation in 
about 24 cases (64.9%) and alteration of bowel habits in 15 patients (48.6%). However, 
pain abdomen and features of obstruction are also reported in 8 cases (21.6%) and 3 
cases (6.1%) respectively.
Ulceroproliferative growth of the rectum was the most common appearance in 
sigmoidoscopy was present in 18 cases (48.6%), whereas annular variety was present in 
12 cases (32.4%), tubular variety was present in 7 cases (19%).
Goligher et al in his study says that lower third of rectum is the most commom 
site of cancer in about 62% of cases,whereas Jarvinen et al found it to be the frequent 
site in 46% of the cases.In our study, the most commom site of tumor is the lower third 
of the rectum in about 26 cases (70.3%).
Issac Hassan et al  reports adenocarcinoma as the most common histopathologic 
type  in  about  90%  of  the  cases,  whereas  our  study  adenocarcinoma  was  the  most 
common  type   in  34  cases  (91.8%).  However,  we  also  had  the  rare  varieties  of 
histopathologic  presentations  like  malignant  melanoma,  neuro-endocrine  tumors  and 
Burkitt’s lymphoma. The last mentioned variety is was seen in an Immunocompromised 
patient(HIV-AIDS).
Curative surgery was possible in 32 cases (86.5% ). Abdomino-perineal resection 
was  done in  25cases  (67.6%)  where the  tumor  is  situated  in  the  lower  third of  the 
rectum, of which one case was done with minimal access method (LAPR). Anterior 
resection was done for the cases when the tumor is situated in the upper and middle third 
of the rectum  in 7 cases (18.9%) of which 2 cases (5.4%) were done by laparoscopic 
method (LAR). Turuman MJ et al says that curative surgey was possible in 65.6% of 
the  cases.  Colostomy  alone  was  done  in  5  cases  (13.5%).  The  main  causes  of 
inoperabilty were frozen pelvis, sacral invasion and prostatic invasion.
Duke’s staging was done in 32 cases of which 12 cases were in stage A (37.5%), 
13 cases (40.6%) were in Stage B, 7 cases (21.9%) were in stage C. Boland CR et al in 
his study series reported 10% of the cases in stage A, 50% in stage B and 30% in stage 
C.
Wound infection either in the perineum or abdomen was the most common cause 
of morbidity. It was present in ten cases. 2 patients required secondary suturing whereas 
others healed with daily dressings. Retention of urine was also a common complication. 
Sexual dysfunction was also present in some cases.
Corman et al reported the incidence of mortality of 6.7% in his study series. 2 
patients  died  in  our  study  period  (5.4%).  One  patient  underwent  laparoscopic  APR 
afterwhich the patient never recovered from anaesthesia and was in Intensive care unit 
under artificial ventilation. Patient died on the sixth post operative day. Another patient 
underwent APR,who was also immunocompromised, died due to septicemia.
CONCLUSION
Carcinoma of the rectum is more common in males when compared to females. 
The peak age of incidence is in the seventh decade with more patients also seen between 
the  ages  of  40-50 years.  Bleeding  per  rectum is  the  most  common type  of  clinical 
presentation followed by alteration of bowel habits.  Ulcero-proliferative growth was the 
most  common macroscopic  appearance of  the tumor on sigmoidoscopy followed by 
annular  variety.  Adenocarcinoma  was  the  most  common histological  type  with  rare 
varieties  like  Malignant  melanoma,  Burkitt’s  lymphoma and Neuro-endocrine  tumor 
should also be borne in mind. Curative surgery either in the form of abdomino-perineal 
resection (APR) or anterior resection (AR) was done in most cases and the patients were 
followed with radio-therapy or chemotherapy in the form of 5-Flurouracil in the post 
operative period.  
The main cause of inoperability is frozen pelvis,  where the growth is adherent 
with the adjacent structures and involvement of multiple nodes. Wound infection, either 
in the abdomen or in the perineum was the most common complication and should be 
given highest antibiotics to prevent it.
There  is  need  to  increase  awareness  through  public  education  about  the 
malignancy and the management. Any adult with complaints of blood or mucus in the 
stools or alteration of bowel habits,  especially over the age of 40 years,  which may 
herald the onset  of carcinoma of the rectum, should be adequately investigated with 
digital rectal examination and proctosigmoidoscopy as this is the only hope of making 
an early diagnosis.
With  modern  diagnostic  techniques  and  improved  therapeutic  interventions, 
carcinoma of the rectum can be cured without morbidity and mortality.
PROFORMA
Name                               Age                Sex             I.P.No
Address
Complaints
     Bleeding PR
    Altered bowel habits
    Mucus stools
    Constipation
    Spurious diarrhea
    Loss of weight 
    Loss of weight
    Abdominal pain
    Fatigue 
    Obstipation
Personal history
    Smoking
    Alcoholism
    Nonvegetarian
Past history
Family history
Investigations
    Hb%
    RFT
    LFT
    AXR-Erect
    CXR-PA  
    ECG  
    USG Abdomen and pelvis
    CT   Abdomen and pelvis
    Sigmoidoscopy 
Preoperative preparation
     Bowel preparation
     Antibiotics
Surgical procedure and findings
Postoperative complications
Follow up
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1 Rahim 64 M 40289 + + + - + Ulceroproliferative < 8 cm APR A WDA
2 Narayanan 54 M 865 - + + - - Ulceroproliferative < 8 cm APR A WDA
3 Appasamy 65 M 10900 + + - - - Ulceroproliferative < 8 cm APR B WDA
4 Jadiajan 65 M 10600 + - - - - Annular > 8 cm AR C PDA
5 Kuppammal 50 F 27219 + - + - + Tubular < 8 cm APR B MDA
6 Meera 63 F 25732 - + - - - Ulceroproliferative < 8 cm APR A WDA
7 Lakshmi 45 F 36789 + - - - - Tubular < 8 cm APR C MDA
8 Elumalai 60 M 34303 + + + - - Annular > 8 cm AR A WDA
9 Manjula 25 F 36117 - + + - - Ulceroproliferative < 8 cm APR B WDA
10 Raja 36 M 13171 + - - - + Ulceroproliferative < 8 cm APR C MDA
11 Rathinavel 55 M 14902 + - - - - Annular < 8 cm
Colosto
my PDA
12 Neela 39 F 16540 + - - - - Annular < 8 cm APR A WDA
13 Marimuthu 48 M 8150 - + + - - Ulceroproliferative < 8 cm APR C MDA
14 Saroja 50 F 20738 + + - - - Ulceroproliferative > 8 cm LAR B WDA
15 Maheswari 25 F 7925 + - - - - Tubular < 8 cm APR A WDA
16 Marimuthu 47 M 15595 - - + - + Ulceroproliferative < 8 cm APR B WDA
17 Babu 24 M 44494 + - - - - Annular > 8 cm LAR B MDA
18 Thiruvengadam 54 M 26548 + + + - - Ulceroproliferative
< 8 
cm APR A MDA
19 Babu 41 M 29003 - - - - - Annular < 8 cm APR C BL
20 Kousalya 71 F 27589 - + - - - Tubular < 8 cm APR B WDA
21 Chinnappan 72 M 31514 + - + - + Ulceroproliferative > 8 cm AR A MDA
22 Kumaravel 51 M 40830 + - - - - Annular > 8 cm AR B MDA
23 Raju 19 M 16329 + - - + - Annular < 8 cm
Colosto
my MDA
24 Rathinum 58 M 27571 + + + - - Ulceroproliferative < 8 cm APR B WDA
25 Sukumaran 62 M 23242 - - - - - Ulceroproliferative > 8 cm APR A WDA
S. 
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26 Marimuthu 61 M 26412 + + - - + Ulceroproliferative < 8 cm LAPR
27 Venkatesan 61 M 26451 + - + - - Tubular < 8 cm APR
28 Ramalingam 56 M 22821 + - - - - Ulceroproliferative > 8 cm APR
29 Arivu 33 M 25168 - + + - + Annular < 8 cm APR
30 Sundaresan 60 M 27820 + + + + - Tubular < 8 cm Colostomy
31 Annammal 40 F 36897 + - - - - Ulceroproliferative > 8 cm AR
32 Kanimozhi 18 F 32343 - + - + - Annular < 8 cm Colostomy
33 Ramalingam 58 M 4670 - + - - - Ulceroproliferative < 8 cm APR
34 Sundarammal 62 F 22460 + + - - - Tubular < 8 cm APR
35 Somasundaram 63 M 17781 - + + - + Ulceroproliferative > 8 cm APR
36 Subramani 61 M 23618 + - - - - Annular < 8 cm Colostomy
37 Pattammal 63 F 36189 - - - - - Annular < 8 cm APR
APR - Abdomino-Perineal Resection. WDA - Well 
Differentiated Adenocarcinoma.
AR - Anterior Resection. MDA - Moderately 
Differentiated Adenocarcinoma.
LAR - Laproscopic Anterior Resection. PDA - Poorly 
Differentiated Adenocarcinoma.
LAPR - Laproscopic Abdomino-Perineal Resection. MM -
Malignant Melanoma.
< 8 cm - Lower one-third. NET - Neuro 
Endocrine Tumor.
> 8 cm - Upper & Middle-third. BL -
Burkitt’s Lymphoma.
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